Peanut Oral Immunotherapy: Is the Second Year the Charm?

Peanut Oral Immunotherapy: Is the Second Year the Charm?

[...]21% of actively treated participants in PALISADE discontinued treatment, over half due to adverse events. [...]although the numbers are small, it appears that the rate of systemic allergic reactions in the second year of OIT remains far higher than that of patients practicing avoidance alone. [...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2021-05, Vol.9 (5), p.1890-1891
Hauptverfasser: Dunlop, Joan H., Wood, Robert A.
Format: Artikel
Sprache:eng
Schlagworte:
Allergens
Drug dosages
FDA approval
Food allergies
Hypersensitivity
Immunotherapy
Patients
Quality of life
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[...]21% of actively treated participants in PALISADE discontinued treatment, over half due to adverse events. [...]although the numbers are small, it appears that the rate of systemic allergic reactions in the second year of OIT remains far higher than that of patients practicing avoidance alone. [...]in terms of efficacy, the results of the exit food challenges suggested modest increases in challenge thresholds with an additional year of daily treatment.
ISSN:2213-2198
2213-2201
DOI:10.1016/j.jaip.2021.01.013